Last reviewed · How we verify
Cyclophosphamide and azathioprine
This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function.
This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function. Used for Autoimmune diseases (likely vasculitis, lupus nephritis, or other systemic autoimmune conditions based on typical Phase 3 use).
At a glance
| Generic name | Cyclophosphamide and azathioprine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Immunosuppressive agents / Cytotoxic agents |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA and causes cell death, particularly affecting rapidly dividing cells including lymphocytes. Azathioprine is a prodrug converted to 6-mercaptopurine, which inhibits purine synthesis and reduces T and B cell proliferation. Together, they provide potent immunosuppression through complementary mechanisms.
Approved indications
- Autoimmune diseases (likely vasculitis, lupus nephritis, or other systemic autoimmune conditions based on typical Phase 3 use)
Common side effects
- Myelosuppression / leukopenia
- Infection
- Nausea / vomiting
- Hemorrhagic cystitis
- Alopecia
- Secondary malignancy
Key clinical trials
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) (PHASE3)
- Reduced Intensity Transplantation for Severe Sickle Cell Disease (PHASE2)
- Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (PHASE2)
- Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: